These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28760329)

  • 1. Micro-elimination - A path to global elimination of hepatitis C.
    Lazarus JV; Wiktor S; Colombo M; Thursz M;
    J Hepatol; 2017 Oct; 67(4):665-666. PubMed ID: 28760329
    [No Abstract]   [Full Text] [Related]  

  • 2. Global hepatitis C elimination: an investment framework.
    Pedrana A; Howell J; Scott N; Schroeder S; Kuschel C; Lazarus JV; Atun R; Baptista-Leite R; 't Hoen E; Hutchinson SJ; Aufegger L; Peck R; Sohn AH; Swan T; Thursz M; Lesi O; Sharma M; Thwaites J; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):927-939. PubMed ID: 32730786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WORLD HEPATITIS SUMMIT HARNESSES GLOBAL MOMENTUM TO ELIMINATE VIRAL HEPATITIS.
    Cent Eur J Public Health; 2015 Sep; 23(3):272. PubMed ID: 26618210
    [No Abstract]   [Full Text] [Related]  

  • 4. "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination.
    Lancaster K; Rhodes T; Rance J
    Int J Drug Policy; 2020 Jun; 80():102419. PubMed ID: 30975593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C: global prevalence.
    Wkly Epidemiol Rec; 1997 Nov; 72(46):341-4. PubMed ID: 9385865
    [No Abstract]   [Full Text] [Related]  

  • 6. Remaining challenges in HCV elimination.
    Capraru C; Feld JJ
    J Hepatol; 2021 Apr; 74(4):964-965. PubMed ID: 33589319
    [No Abstract]   [Full Text] [Related]  

  • 7. New WHO guidance for country validation of viral hepatitis B and C elimination.
    Easterbrook P; Luhmann N; Newman M; Walsh N; Lesi O; Doherty M
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):778-780. PubMed ID: 34384530
    [No Abstract]   [Full Text] [Related]  

  • 8. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations.
    Lazarus JV; Safreed-Harmon K; Thursz MR; Dillon JF; El-Sayed MH; Elsharkawy AM; Hatzakis A; Jadoul M; Prestileo T; Razavi H; Rockstroh JK; Wiktor SZ; Colombo M
    Semin Liver Dis; 2018 Aug; 38(3):181-192. PubMed ID: 29986353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
    Ward JW; Hinman AR
    Gastroenterology; 2019 Jan; 156(2):297-310. PubMed ID: 30391470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.
    Sonderup MW; Afihene M; Ally R; Apica B; Awuku Y; Cunha L; Dusheiko G; Gogela N; Lohouès-Kouacou MJ; Lam P; Lesi O; Mbaye PS; Musabeyezu E; Musau B; Ojo O; Rwegasha J; Scholz B; Shewaye AB; Tzeuton C; Kassianides C; Spearman CW;
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):910-919. PubMed ID: 29132760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The draft new World Health Organization program "global technical strategy for malaria control and elimination for 2016-2025"].
    Baranova AM
    Med Parazitol (Mosk); 2015; (1):60-2. PubMed ID: 25850324
    [No Abstract]   [Full Text] [Related]  

  • 12. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
    J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reinventing hepatitis C: from interferon deficiency to control.
    Wodak A; Crofts N
    Aust N Z J Public Health; 1996 Jun; 20(3):231-2. PubMed ID: 8768410
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough.
    Page-Shafer K; Hahn JA; Lum PJ
    AIDS; 2007 Sep; 21(14):1967-9. PubMed ID: 17721105
    [No Abstract]   [Full Text] [Related]  

  • 16. Mobilising a global response to hepatitis: Lessons learned from the HIV movement.
    Taaffe J; Wilson D
    Glob Public Health; 2018 Apr; 13(4):473-488. PubMed ID: 27748158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who: four ways to reduce hepatitis infections in people who inject drugs.
    Cent Eur J Public Health; 2012 Sep; 20(3):207. PubMed ID: 23285521
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments.
    Wait S; Kell E; Hamid S; Muljono DH; Sollano J; Mohamed R; Shah S; Mamun-Al-Mahtab ; Abbas Z; Johnston J; Tanwandee T; Wallace J
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):248-255. PubMed ID: 28404097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis elimination by 2030: Progress and challenges.
    Waheed Y; Siddiq M; Jamil Z; Najmi MH
    World J Gastroenterol; 2018 Nov; 24(44):4959-4961. PubMed ID: 30510370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.